RVL Pharmaceuticals plc Fair Value, Option, Aggregate Differences, Long-term Debt Instruments
RVL Pharmaceuticals plc had Fair Value, Option, Aggregate Differences, Long-term Debt Instruments of $75.00 million as of 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Notes › Fair Value Disclosures
us-gaap:FairValueOptionAggregateDifferencesLongTermDebtInstruments · last filed 2023-08-14
- 2023-06-30: Fair Value, Option, Aggregate Differences, Long-term Debt Instruments $75.00M.
- 2023-03-31: Fair Value, Option, Aggregate Differences, Long-term Debt Instruments $67.13M.
- 2022-12-31: Fair Value, Option, Aggregate Differences, Long-term Debt Instruments $75.00M.
- 2021-12-31: Fair Value, Option, Aggregate Differences, Long-term Debt Instruments $55.00M.
| Period end | Fair Value, Option, Aggregate Differences, Long-term Debt Instruments |
|---|---|
| 2023-06-30 | $75.00M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $67.13M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $75.00M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $55.00M 10-K · filed 2023-03-20 |
| 2020-12-31 | $221.40M 10-K · filed 2022-03-30 |